Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5093 in MET-Altered Advanced NSCLC
2023-506248-18-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of davutamig in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Number of patients with dose limiting toxicities (DLTs), Incidence and severity of treatment-emergent adverse events (TEAEs) - Phase 1 and 5 more. Started Jun 2024; status: completed.
02
Drugs
davutamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506248-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506248-18-00.